Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This study will test how well Regorafenib controls disease progression in urothelial cancer
(cancer occurring in the urinary bladder, ureters, or renal pelvis) following previous
therapy with chemotherapy.